Preparation and characterisation of a soy lecithin‐based self‐microemulsifying drug delivery system of resveratrol
Source abstract
Abstract
The aim of this reported work was to develop and characterise a soy lecithin‐based self‐microemulsifying drug delivery system (SMEDDS) of resveratrol to enhance its oral delivery. Using high‐performance liquid chromatography, the solubility of resveratrol in various materials was determined. The effects and the ratios of the oil, surfactant and co‐surfactant on forming an efficient and stable SMEDDS were investigated using pseudo‐tertiary phase diagrams. The oil content, soy lecithin content and drug loading were optimised. The optimal formulation was composed of greoil gtcc, Cremophor EL, 1,2‐propanediol, soy lecithin and resveratrol (16.1/46/23/6.9/8, %w/w). The final SMEDDS was characterised by particle size, zeta potential and by transmission electron microscopy. The dilution volume in various aqueous media had some effect on the particle size. An in‐vitro release test showed a complete release of resveratrol from the SMEDDS in approximately 180 min. The stability investigation results indicated that the formulation was stable for 12 weeks.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Sirtuins and Resveratrol in Medicine · Biochemical effects in animals · Toxin Mechanisms and Immunotoxins
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Bioelectronics School of Biological Science and Medical Engineering Southeast University Nanjing 210096 People's Republic of China
Collaborative Innovation Center of Suzhou Nano Science and Technology Suzhou 215123 People's Republic of China
State Key Laboratory of Biomembrane and Membrane Biotechnology School of Life Sciences Tsinghua University Beijing 100084 People's Republic of China
Jiangsu Longliqi Bioscience Co. Ltd Suzhou 215555 People's Republic of China
References (25)
Show source-provided references
1. 10.1073/pnas.94.25.1413810.1073/pnas.94.25.14138 ↗
2. Chemistry, stability and bioavailability of resveratrol
3. Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P‐glycoprotein inhibition by resveratrol
4. 10.1002/mnfr.20090043710.1002/mnfr.200900437 ↗
5. 10.1089/15230860131720356710.1089/152308601317203567 ↗
6. 10.1016/j.fct.2012.11.03110.1016/j.fct.2012.11.031 ↗
7. 10.1517/17425247.2011.58165510.1517/17425247.2011.581655 ↗
8. 10.1111/j.1749‐6632.2010.05842.x10.1111/j.1749‐6632.2010.05842.x ↗
9. 10.1124/dmd.104.00088510.1124/dmd.104.000885 ↗
10. 10.2133/dmpk.20.24410.2133/dmpk.20.244 ↗
11. 10.1016/j.ijpharm.2009.03.00810.1016/j.ijpharm.2009.03.008 ↗
12. 10.1016/j.biopha.2013.04.00110.1016/j.biopha.2013.04.001 ↗
13. VonderscherJ.MeinzerA.: ‘Rationale for the development of Sandimmune Neoral’ Transplant Proc. 1994 26 pp.2925–7
14. 10.1016/S0939‐6411(00)00089‐810.1016/S0939‐6411(00)00089‐8 ↗
15. 10.1016/S0378‐5173(00)00614‐110.1016/S0378‐5173(00)00614‐1 ↗
16. 10.1016/j.ijpharm.2007.12.02610.1016/j.ijpharm.2007.12.026 ↗
17. 10.3109/03639045.2012.74988810.3109/03639045.2012.749888 ↗
18. 10.1023/A:100615610446510.1023/A:1006156104465 ↗
19. 10.1016/j.livsci.2008.01.01410.1016/j.livsci.2008.01.014 ↗
20. 10.1208/s12249‐009‐9234‐110.1208/s12249‐009‐9234‐1 ↗
21. 10.1016/j.colsurfa.2011.12.02510.1016/j.colsurfa.2011.12.025 ↗
22. 10.2478/v10007‐012‐0022‐110.2478/v10007‐012‐0022‐1 ↗
23. 10.1016/j.ejpb.2005.12.00510.1016/j.ejpb.2005.12.005 ↗
24. 10.1208/s12249‐010‐9385‐010.1208/s12249‐010‐9385‐0 ↗
25. 10.3109/1083745090328653710.3109/10837450903286537 ↗